UB Paderborn / Katalog / Suche / in CDI

Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial

PloS one, 2019-09, Vol.14 (9), p.e0222178

2019

Volltextzugriff (PDF)

DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial

PloS one, 2018-11, Vol.13 (11), p.e0206837-e0206837

2018

Volltextzugriff (PDF)

Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting

Clinical cancer research, 2007-11, Vol.13 (21), p.6386-6395

2007

Volltextzugriff (PDF)

Phase 1 study of pandemic H1 DNA vaccine in healthy adults

PloS one, 2015-04, Vol.10 (4), p.e0123969-e0123969

2015

Volltextzugriff (PDF)

Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells

Journal of clinical oncology, 2003-11, Vol.21 (21), p.4016-4026

2003

Volltextzugriff (PDF)

DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial

PloS one, 2015-05, Vol.10 (5), p.e0125914

2015

Volltextzugriff (PDF)

Immunologic and Clinical Outcomes of Vaccination With a Multiepitope Melanoma Peptide Vaccine Plus Low-Dose Interleukin-2 Administered Either Concurrently or on a Delayed Schedule

Journal of clinical oncology, 2004-11, Vol.22 (22), p.4474-4485

2004

Volltextzugriff (PDF)

Publication practices and attitudes towards evidence-based medicine in central Asia

The Lancet global health, 2013-08, Vol.1 (2), p.e73-e74

2013

Volltextzugriff (PDF)

An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial

npj vaccines, 2017-06, Vol.2 (1), p.15-15, Article 15

2017

Volltextzugriff (PDF)

Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

The lancet respiratory medicine, 2021-10, Vol.9 (10), p.1111-1120

2021

Volltextzugriff (PDF)

Evaluation of the Sentinel Immunized Node for Immune Monitoring of Cancer Vaccines

Annals of surgical oncology, 2008-12, Vol.15 (12), p.3538-3549

2008

Volltextzugriff (PDF)

Sequential Immune Escape and Shifting of T Cell Responses in a Long-Term Survivor of Melanoma

The Journal of immunology (1950), 2005-06, Vol.174 (11), p.6863-6871

2005

Volltextzugriff (PDF)

VRC 311: Phase I Clinical Trial of a Virus-Like Particle Chikungunya Vaccine in Healthy Adults

Journal of allergy and clinical immunology, 2013-02, Vol.131 (2), p.AB330-AB330

2013

Volltextzugriff (PDF)

Terminal modifications inhibit proteolytic degradation of an immunogenic mart‐127–35 peptide: Implications for peptide vaccines

International journal of cancer, 1999-10, Vol.83 (3), p.326-334

1999

Volltextzugriff (PDF)

Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients

International journal of cancer, 2001-06, Vol.92 (5), p.703-711

2001

Volltextzugriff (PDF)

A proof of concept for structure-based vaccine design targeting RSV in humans

Science (American Association for the Advancement of Science), 2019-08, Vol.365 (6452), p.505-509

2019

Volltextzugriff (PDF)

Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial

Nature medicine, 2022-05, Vol.28 (5), p.1022-1030

2022

Volltextzugriff (PDF)

Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial

The Lancet infectious diseases, 2023-12, Vol.23 (12), p.1408-1417

2023

Volltextzugriff (PDF)

Protection Against Vaginal SIV Transmission with Microencapsulated Vaccine

Science (American Association for the Advancement of Science), 1993-05, Vol.260 (5112), p.1323-1327

1993

Volltextzugriff (PDF)

Low-dose IL-2 induces cytokine cascade, eosinophilia, and a transient Th2 shift in melanoma patients

Cancer Immunology, Immunotherapy, 2005-11, Vol.54 (11), p.1095-1105

2005

Volltextzugriff (PDF)

Defective Human Leukocyte Antigen Class I-associated Antigen Presentation Caused by a Novel β2-Microglobulin Loss-of-function in Melanoma Cells

The Journal of biological chemistry, 2006-07, Vol.281 (27), p.18763-18773

2006

Volltextzugriff (PDF)

Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults: e0123969

PloS one, 2015-04, Vol.10 (4)

2015

Volltextzugriff (PDF)

Defective Human Leukocyte Antigen Class I-associated Antigen Presentation Caused by a Novel beta sub(2)-Microglobulin Loss-of-function in Melanoma Cells

The Journal of biological chemistry, 2006-07, Vol.281 (27), p.18763-18773

2006

Volltextzugriff (PDF)

Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells

The Journal of biological chemistry, 2006-07, Vol.281 (27), p.18763

2006

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial

DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial

Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting

Phase 1 study of pandemic H1 DNA vaccine in healthy adults

Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells

DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial

Immunologic and Clinical Outcomes of Vaccination With a Multiepitope Melanoma Peptide Vaccine Plus Low-Dose Interleukin-2 Administered Either Concurrently or on a Delayed Schedule

Publication practices and attitudes towards evidence-based medicine in central Asia

An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial

Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

Evaluation of the Sentinel Immunized Node for Immune Monitoring of Cancer Vaccines

Sequential Immune Escape and Shifting of T Cell Responses in a Long-Term Survivor of Melanoma

VRC 311: Phase I Clinical Trial of a Virus-Like Particle Chikungunya Vaccine in Healthy Adults

Terminal modifications inhibit proteolytic degradation of an immunogenic mart‐127–35 peptide: Implications for peptide vaccines

Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients

A proof of concept for structure-based vaccine design targeting RSV in humans

Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial

Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial

Protection Against Vaginal SIV Transmission with Microencapsulated Vaccine

Low-dose IL-2 induces cytokine cascade, eosinophilia, and a transient Th2 shift in melanoma patients

Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials

Defective Human Leukocyte Antigen Class I-associated Antigen Presentation Caused by a Novel β2-Microglobulin Loss-of-function in Melanoma Cells

Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults: e0123969

Defective Human Leukocyte Antigen Class I-associated Antigen Presentation Caused by a Novel beta sub(2)-Microglobulin Loss-of-function in Melanoma Cells

Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells

Suchergebnisse filtern